About Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist used in metabolic research. Supplied as a lyophilized powder for laboratory studies investigating dual incretin receptor activation, insulin-related signaling pathways, and glucose homeostasis mechanisms in controlled experimental models. Each batch undergoes analytical verification for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: >95-99 (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.
Recent research on Tirzepatide: GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort
Read Full Study on PubMedTirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.
Recent research on Tirzepatide: Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents.
Read Full Study on PubMedAdditional Studies
Tirzepatide reduces intracellular lipid content by promoting the browning of white fat via the cAMP signaling pathway.
Recent research on Tirzepatide: Tirzepatide reduces intracellular lipid content by promoting the browning of white fat via the cAMP signaling pathway.
Read on PubMedExploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends.
Recent research on Tirzepatide: Exploring the Potential Link Between Tirzepatide and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Evidence from FAERS and Google Trends.
Read on PubMedBody Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.
Recent research on Tirzepatide: Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.
Read on PubMed12-Month Weight Loss and Adherence Predictors in a Real-World UK Tirzepatide-Supported Digital Obesity Service: A Retrospective Cohort Analysis.
Recent research on Tirzepatide: 12-Month Weight Loss and Adherence Predictors in a Real-World UK Tirzepatide-Supported Digital Obesity Service: A Retrospective Cohort Analysis.
Read on PubMedTirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis in Diet-induced Obesity Model.
Recent research on Tirzepatide: Tirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis in Diet-induced Obesity Model.
Read on PubMedThe Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.
Recent research on Tirzepatide: The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.
Read on PubMedRelated Research
Purchase Tirzepatide from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.